montelukast + fexofenadine

Montegra is a fixed-dose combination pharmaceutical product developed and marketed by ADN Life Sciences. It is primarily indicated for the symptomatic treatment of allergic conditions, including allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria. The medication combines two distinct mechanisms of action: **montelukast**, a selective cysteinyl leukotriene receptor antagonist, and **fexofenadine**, a second-generation, non-sedating H1-receptor antihistamine. Montelukast works by blocking the CysLT1 receptor, thereby inhibiting the inflammatory effects of leukotrienes which contribute to airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. Fexofenadine acts as a peripheral H1-receptor antagonist, reducing symptoms such as sneezing, rhinorrhea, and itchy eyes. This combination is designed to address both the early-phase histamine-mediated response and the late-phase leukotriene-mediated inflammatory response in allergic diseases.

Brand names

Montegra

Other names

Montelukast Sodium and Fexofenadine Hydrochloride Tablets